Science&Tech All eyes on Galapagos test results By WeeklyNews staff Posted on June 2, 2019 1 min read Share on Facebook Share on Twitter Share on Google+ The presentation of the interim results of the ongoing FINCH 1 study by Galapagos and Gilead Sciences at the kick-off of the European Congress on Rheumatology will attract much attention in the medical community. Experts write that at KBC Securities. They emphasize that choosing this opportunity emphasizes the importance of the Galapagos update. The FINCH 3 study is also presented at the conference, but later during the event. The analysts emphasize that anti-inflammatory filgotinib, for which both tests are used, is an innovative means that is likely to be in high demand. However, they warn that competition with similar means that are already circulating on the market will be fierce. Market researchers expect Galapagos to submit an application for approval of filgotinib to the European Medicines Agency in the second half of this year. KBC is sticking to its buying advice for Galapagos and sticking to the earlier target of 124 euros. Galapagos was 1.5 percent lower at EUR 101.75 around 09.20.